Table 3.
Association of co-expression of UBE2C and cancer stemness markers with survival in oral cancer patients from TCGA database.
| Variable | No. (%) | CHR (95% CI) | p Value * | AHR (95% CI) | p Value † |
|---|---|---|---|---|---|
| Overall survival | |||||
| UBE2C (L) CD44(L) | 38 (14.4) | 1.00 | 1.00 | ||
| UBE2C (H) CD44(L) | 141 (53.4) | 1.30 (0.90–1.88) | 0.166 | 2.91 (1.39–6.08) | 0.004 |
| UBE2C (L) CD44(H) | 17 (6.4) | 0.74 (0.34–1.59) | 0.435 | 1.91 (0.69–5.30) | 0.212 |
| UBE2C (H) CD44(H) | 68 (25.8) | 1.38 (0.92–2.07) | 0.115 | 3.29 (1.51–7.16) | 0.003 |
| UBE2C (L) ALCAM(L) | 51 (19.3) | 1.00 | 1.00 | ||
| UBE2C (H) ALCAM(L) | 171 (64.8) | 1.12 (0.76–1.65) | 0.562 | 2.24 (1.23–4.07) | 0.008 |
| UBE2C (L) ALCAM(H) | 4 (1.5) | 0.83 (0.21–3.37) | 0.795 | 1.81 (0.41–8.07) | 0.438 |
| UBE2C (H) ALCAM(H) | 38 (14.4) | 2.05 (1.32–3.18) | 0.001 | 3.91 (1.99–7.68) | <0.001 |
| UBE2C (L) EPCAM(L) | 51 (19.3) | 1.00 | 1.00 | ||
| UBE2C (H) EPCAM(L) | 141 (53.4) | 1.21 (0.84–1.75) | 0.308 | 2.42 (1.31–4.50) | 0.005 |
| UBE2C (L) EPCAM(H) | 4 (1.5) | 0.90 (0.28–2.91) | 0.862 | 1.93 (0.53–6.98) | 0.319 |
| UBE2C (H) EPCAM(H) | 68 (25.8) | 2.50 (1.01–2.24) | 0.045 | 2.99 (1.55–5.78) | 0.001 |
| Disease-free survival | |||||
| UBE2C (L) CD44(L) | 37 (16.4) | 1.00 | 1.00 | ||
| UBE2C (H) CD44(L) | 10 (4.4) | 2.15 (0.77–5.95) | 0.143 | 3.90 (1.04–14.57) | 0.043 |
| UBE2C (L) CD44(H) | 149 (65.9) | 0.82 (0.47–1.40) | 0.461 | 1.75 (0.69–4.48) | 0.242 |
| UBE2C (H) CD44(H) | 30 (13.3) | 1.89 (1.00–3.60) | 0.051 | 3.21 (1.13–9.12) | 0.029 |
| UBE2C (L) ALCAM(L) | 130 (57.5) | 1.00 | 1.00 | ||
| UBE2C (H) ALCAM(L) | 18 (8.0) | 0.98 (0.35–2.70) | 0.961 | 1.15 (0.40–3.30) | 0.792 |
| UBE2C (L) ALCAM(H) | 56 (24.8) | 0.80 (0.42–1.52) | 0.492 | 0.99 (0.50–1.96) | 0.977 |
| UBE2C (H) ALCAM(H) | 22 (9.7) | 2.84 (1.50–5.40) | 0.001 | 2.87 (1.45–5.67) | 0.002 |
| UBE2C (L) EPCAM(L) | 158 (69.9) | 1.00 | 1.00 | ||
| UBE2C (H) EPCAM(L) | 32 (14.2) | 1.25 (0.61–2.56) | 0.537 | 1.42 (0.68–2.97) | 0.354 |
| UBE2C (L) EPCAM(H) | 28 (12.4) | 0.78 (0.33–1.82) | 0.565 | 0.93 (0.39–2.23) | 0.878 |
| UBE2C (H) EPCAM(H) | 8 (3.5) | 4.99 (2.24–11.12) | <0.001 | 5.24 (2.30–11.95) | <0.001 |
Abbreviations: OSCC, Oral squamous cell carcinoma; CHR, crude hazard ratio; CI, confidence interval; AHR, adjusted hazard ratio; AJCC, American Joint Committee on Cancer; RT, radiotherapy. * p values were estimated by Cox’s regression. † p values were adjusted for cell differentiation (moderate + poor vs. well) and AJCC pathological stage (stage III + IV vs. stage I + II) by multivariate Cox’s regression. Bold values denote statistically significant.